RIPK4 activates an IRF6-mediated proinflammatory cytokine response in keratinocytes

Mei Qi Kwa¹, Glen M. Scholz¹, and Eric C. Reynolds*

Oral Health Cooperative Research Centre, Melbourne Dental School, Bio21 Molecular
Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010,
Australia.

¹M Kwa and G Scholz contributed equally to this study.

Running Title: RIPK4-elicited keratinocyte inflammation

Abbreviations: RIPK4, receptor-interacting protein kinase 4; IRF6, interferon regulatory
factor 6; PKC, protein kinase C.

*Corresponding author: E-mail address: e.reynolds@unimelb.edu.au

ABSTRACT

Keratinocytes of the oral mucosa and epidermis play key roles in host defense. In addition to functioning as a physical barrier, they also produce cytokines to elicit inflammation in response to infection or injury. We recently established that receptor-interacting protein kinase 4 (RIPK4) and interferon regulatory factor 6 (IRF6) function as a cell-intrinsic signaling axis to regulate keratinocyte differentiation. In this study, we have demonstrated a functional relationship between RIPK4 and IRF6 in the control of proinflammatory cytokine expression in keratinocytes. The overexpression of RIPK4 by oral keratinocytes induced the strong expression of CCL5 and CXCL11. In contrast, the expression of other cytokines (e.g. IL8 and TNF) was largely unaffected, thus demonstrating specificity in the induction of proinflammatory cytokine expression by RIPK4. CCL5 and CXCL11 expression were also induced in response to the activation of the PKC pathway, and gene silencing experiments indicated that their inducible expression was dependent on RIPK4 and IRF6. Moreover, gene reporter assays suggested that RIPK4 induces CCL5 and CXCL11 expression by stimulating the transactivation of their promoters by IRF6. Accordingly, our findings suggest that the RIPK4-IRF6 signaling axis plays a multifaceted role in barrier epithelial homeostasis through its regulation of both keratinocyte inflammation and differentiation.

Keywords: Keratinocyte; CCL5; CXCL11; RIPK4; IRF6.

1. Introduction

The oral mucosa and epidermis function as protective barriers against mechanical and chemical damage and biological insults (e.g. microbial pathogens) [1]. The homeostatic maintenance of these barriers requires a delicate balance between proliferation and differentiation where epithelial stem cells in the basal layer periodically withdraw from the cell cycle and differentiate into keratinocytes as they migrate towards the surface [2]. When the integrity of these barriers is compromised, for instance following injury, a wound healing response is triggered. The re-epithelialization phase of the response involves the proliferation and migration of keratinocytes to the site of injury, and differentiation to restore barrier integrity [3].

Keratinocytes also play active roles in providing protection against infection [4]. They express various pattern recognition receptors, including Toll-like receptors (TLRs), which positions them to carry out immunosurveillance [5]. Keratinocytes respond to pathogens by producing cytokines, including interleukin-8 (IL8) and chemokine (C-C motif) ligand 5 (CCL5), which elicit local inflammation through the activation and recruitment of immune cells. IL8 is a key mediator of the activation and recruitment of neutrophils to sites of infection [6], and is critical for periodontal homeostasis due to the presence of a polymicrobial biofilm that accretes to the surface of the teeth [7]. CCL5, whose expression is likewise upregulated in activated keratinocytes [8], is chemotactic for various immune cell populations, including T cells, monocytes, eosinophils, and mast cells [9]. Despite being important mediators of host protection, the overproduction of cytokines by keratinocytes also contributes to the pathogenesis of several chronic inflammatory diseases (e.g. periodontitis, psoriasis, and atopic dermatitis) [7, 10, 11].

Receptor-interacting protein kinase 4 (RIPK4) is a key regulator of keratinocyte differentiation, as indicated by the disorganized and expanded epidermis of Ripk4-deficient mice [12]. Moreover, mutations in RIPK4 cause Bartsocas-Papas syndrome, a congenital

syndrome that is characterized by severe epidermal abnormalities, and typically causes death early in life [13, 14]. We recently demonstrated that RIPK4, which functions in the protein kinase C (PKC) pathway [15, 16], regulates keratinocyte differentiation by directly stimulating the transactivator function of interferon regulatory factor 6 (IRF6) [17]. IRF6 is a key transcriptional regulator of keratinocyte differentiation and regulates the switch from proliferation to differentiation by transactivating differentiation-associated genes (e.g. Grainyhead-Like 3) [17-20]. RIPK4 has also been shown to stimulate the activation of NF- κ B [13, 16, 17, 21, 22], which is also a key transcriptional regulator of epithelial homeostasis [23].

Significantly, RIPK4 function may also extend to the regulation of inflammation. Mice with epidermal-specific expression of a Ripk4 transgene developed spontaneous inflammation that was exacerbated further by the topical application of the well-established skin irritant and PKC agonist, phorbol myristate acetate [24]. Given that RIPK4 and IRF6 function as a signaling axis downstream of PKC activation to promote keratinocyte differentiation [17], we investigated if the pathway also regulates proinflammatory cytokine expression in keratinocytes. The overexpression of RIPK4 in keratinocytes was sufficient to induce the strong expression of CCL5 and chemokine (C-X-C motif) ligand 11 (CXCL11). Moreover, gene silencing and gene reporter experiments indicated that RIPK4 and IRF6 function together in the PKC pathway to stimulate CCL5 and CXCL11 expression. Therefore, our findings potentially extend the RIPK4-IRF6 signaling axis to the regulation of inflammation of the oral mucosa and epidermis through its control of cytokine expression in keratinocytes.

2. Materials and methods

2.1 Reagents

Cell culture medium (Keratinocyte serum-free medium, Dulbecco's-modified Eagle's medium (DMEM), and Opti-MEM I reduced serum medium) and supplements (human EGF, bovine

pituitary extract, penicillin/streptomycin, and GlutaMax-1), fetal bovine serum (FBS), Lipofectamine 2000 and Lipofectamine RNAiMAX transfection reagents, and the Silencer Select RIPK4 siRNA were from Life Technologies. KGM-Gold keratinocyte growth medium was from Lonza. The ON-TARGETplus IRF6 siRNA was from GE Healthcare. FuGENE 6 transfection reagent was from Promega. Phorbol myristate acetate, and the HRP-conjugated anti-FLAG (M2) antibody were from Sigma-Aldrich. The anti-HSP90 antibody was from BD Biosciences, and the human IL8 and CCL5 ELISA kits were from Life Research.

2.2 Expression plasmids

The expression plasmids encoding FLAG-tagged mouse Ripk4 [15] and HA-tagged human IRF6 [25] have been described.

2.3 Cell culture

The human oral keratinocyte cell line, OKF6/TERT-2, was cultured in Keratinocyte serum-free medium supplemented with 0.2 ng/ml human EGF, 25 µg/ml bovine pituitary extract, 0.4 mM CaCl₂, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM GlutaMax-1. Normal human epidermal keratinocytes were cultured in KGM-Gold medium according to the protocol provided by the supplier (Lonza). HEK293T cells were cultured in DMEM medium supplemented with 10% FBS, 100 units/ml Penicillin, 100 µg/ml Streptomycin, and 2 mM GlutaMax-1. All cells were cultured at 37°C in a humidified atmosphere of 5% CO₂.

2.4 Overexpression and siRNA-mediated gene silencing

A reverse-transfection protocol was used for the transfection of OKF6/TERT-2 cells and primary human epidermal keratinocytes. For overexpression, the Ripk4 plasmid was diluted in 100 µl Opti-MEM I reduced serum medium, mixed with 100 µl Opti-MEM medium containing 1 µl Lipofectamine 2000 transfection reagent, and incubated at room temperature

for 15-20 min. For gene silencing, the siRNA was diluted to 120 nM with 100 µl Opti-MEM I medium, mixed with 100 µl Opti-MEM I medium containing 1 µl Lipofectamine RNAiMAX transfection reagent, and incubated at room temperature for 15-20 min. Keratinocytes (5×10^5 cells for overexpression; 2×10^5 cells for gene silencing) in 1 ml of antibiotic-free growth medium were seeded into 12-well plates and the transfection cocktail added. For gene overexpression experiments, the cells were analyzed 24 h post-transfection. For gene silencing experiments, the medium was replaced after 16 h, and the cells treated with phorbol myristate acetate 48 h (OKF6/TERT-2 cells) or 72 h (normal human epidermal keratinocytes) post-transfection.

2.5 Phorbol myristate acetate stimulation

OKF6/TERT-2 cells and normal human epidermal keratinocytes were allowed to adhere overnight. Thereafter, the cells were stimulated with 100 ng/ml phorbol 12-myristate 13-acetate (PMA) in dimethylsulfoxide (DMSO), while time-matched control cells were treated with 0.1% DMSO.

2.6 RNA purification and reverse-transcription

Total RNA was purified using the ReliaPrep RNA Cell miniprep system (Promega), which includes an on-column DNase-treatment step. RNA was reverse-transcribed into cDNA using GoScript Reverse Transcriptase (Promega) and random primers.

2.7 Quantitative real-time PCR

Quantitative real-time PCR (qPCR) was performed in triplicate using GoTaq Probe qPCR Master Mix (Promega) and pre-developed TaqMan assays (Life Technologies) for the following genes: CCL5 (Hs00174575_m1), CXCL11 (Hs00171138_m1), IL8 (Hs00174103_m1), IRF6 (Hs00196213_m1), RIPK4 (Hs01062501_m1), Ripk4

(Mm00458366_m1), and TNF (Hs0113624_g1). Real-time PCR was performed on an ABI PRISM 7900HT (Applied Biosystems) or QuantStudio 7 Flex (Life Technologies), and the data normalized against HPRT gene expression [26].

2.8 Cell lysis and Western blotting

Cells were washed twice with ice-cold PBS, and then lysed (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 10 mM NaF, 10 mM β -glycerol phosphate, and CompleteTM protease inhibitors) on ice for 60 min. Thereafter, the lysates were clarified by centrifugation (13,000 x *g* for 10 min at 4°C) and protein concentrations measured using a protein assay kit (Bio-Rad). Lysates were subjected to electrophoresis on 10% Nu-PAGE gels, followed by Western blotting according to standard protocols. Immunoreactive bands were visualized using ECL reagents (Millipore) and a LAS-3000 Imager (Fujifilm).

2.9 Enzyme-linked immunosorbent assays (ELISA)

ELISA assays were performed by incubating diluted culture supernatants and standards in 96-well microplates for 2 h. The wells were washed prior to the addition of biotinylated anti-IL8 and anti-CCL5 antibodies according to the manufacturer's instructions. After incubation at room temperature for 2 h, the plates were washed and then incubated with a streptavidin-HRP conjugate for 45 min. The plates were again washed, 3,3',5,5'-tetramethylbenzidine substrate added, and color development measured at 450 nm using a microplate reader (Model 680, Bio-Rad).

2.10 Gene promoter reporter assays

HEK293T cells were seeded in 12-well tissue culture plates (3×10^5 cells per well) and transfected in duplicate the next day using FuGENE 6 transfection reagent. The total amount

of plasmid in each transfection was kept constant using empty plasmid. The cells were lysed 24 h post-transfection with Passive Lysis Buffer (Promega), and assayed for firefly and *Renilla* luciferase activity using the Dual-Glo luciferase assay system and a GloMax 96 microplate luminometer (Promega, USA). *Renilla* luciferase activity was used to normalize transfection efficiencies. The luciferase-based CCL5, CXCL11, and IL8 gene promoter reporter plasmids were as previously reported [27-29]. The pRL-TK luciferase reporter plasmid was from Promega.

2.11 Statistical analysis

Data combined from at least three independent experiments are presented as the mean $\pm$ SEM. Statistical analyses were performed using GraphPad Prism software version 6.01 (GraphPad Software). Differences between two groups were evaluated using the Student's *t* test. For multiple comparisons, statistical analysis was performed using a one-way analysis of variance (ANOVA). A *p* value <0.05 was considered to be statistically significant.

3. Results

3.1 Overexpression of RIPK4 induces proinflammatory cytokine expression in keratinocytes

Although RIPK4 is a key regulator of keratinocyte differentiation [12, 17], its transgenic expression in the epidermis of mice causes spontaneous inflammation [24]. Therefore, we investigated if the overexpression of RIPK4 in keratinocytes was sufficient to induce the expression of proinflammatory cytokines. Briefly, OKF6/TERT-2 human oral keratinocytes (hereafter referred to as OKF6 cells) were transfected with a plasmid expressing FLAG-tagged mouse Ripk4. The overexpression of FLAG-Ripk4 was confirmed by qPCR (**Fig. 1A**) and Western blotting with an anti-FLAG antibody (**Fig. 1B**). The overexpression of Ripk4 in OKF6 cells resulted in a 3-fold increase in IL8 mRNA levels (**Fig. 1C**). IL8 protein levels in the culture medium were also moderately increased (**Fig 1D**). Tumor necrosis factor (TNF)

mRNA levels were also weakly affected by the overexpression of Ripk4 (**Fig. 1E**). In contrast to IL8 and TNF, however, CCL5 gene expression was strongly induced (>150-fold) in response to the overexpression of Ripk4 (**Fig. 1F**); CCL5 protein levels in the culture medium were also greatly increased (**Fig. 1G**). Similarly, the overexpression of Ripk4 resulted in the strong induction (>900-fold) of CXCL11 gene expression (**Fig. 1H**). These data strongly suggest that RIPK4 is a key regulator of CCL5 and CXCL11 gene expression in keratinocytes.

3.2 Activation of the PKC pathway induces CCL5 and CXCL11 expression in keratinocytes

RIPK4 has been shown to function downstream of PKC [15, 16], for example to promote keratinocyte differentiation [17]. Given our findings above, we tested the ability of PKC to regulate CCL5 and CXCL11 gene expression. The stimulation of OKF6 cells with the PKC agonist phorbol myristate acetate (PMA) resulted in the strong upregulation of CCL5 gene expression (**Fig. 2A**). The expression levels of CXCL11 were also found to be strongly upregulated in PMA-treated cells (**Fig. 2B**). In contrast to the overexpression of Ripk4 (**Fig. 1**), the stimulation of OKF6 cells with PMA induced strong IL8 (**Fig. 2C**) and TNF (**Fig. 2D**) gene expression. We also examined the effects of PMA stimulation on RIPK4 gene expression. Although declining moderately initially, RIPK4 mRNA levels returned to pre-stimulus levels by 6 h post-PMA stimulation, and had moderately increased after 24 h of PMA stimulation (**Fig. 2E**). Collectively, these findings indicate that the PKC pathway regulates the expression of CCL5 and CXCL11, along with IL8 and TNF, in keratinocytes.

3.3 RIPK4 regulates the induction of proinflammatory cytokine expression by the PKC pathway in keratinocytes

To determine if RIPK4 was necessary for the upregulation of CCL5, CXCL11, IL8 and TNF gene expression by the PKC pathway, RIPK4 expression was silenced prior to stimulating the

cells with PMA. The transfection of OKF6 cells with a RIPK4 siRNA, which reduced RIPK4 mRNA levels by >80% (**Fig. 3A**), strongly inhibited (>65%) the stimulation of CCL5 gene expression by PMA (**Fig. 3B**). Similarly, the induction of CXCL11 expression was also greatly inhibited in cells transfected with the RIPK4 siRNA (**Fig. 3C**). The silencing of RIPK4 also inhibited the PMA-inducible expression of IL8 (**Fig. 3D**) and TNF (**Fig. 3E**). The same gene silencing approach was taken to establish if RIPK4 likewise regulates the PMA-inducible expression of these cytokines in epidermal keratinocytes. The silencing of RIPK4 gene expression in normal human epidermal keratinocytes consistently reduced PMA-inducible CCL5 expression (**Fig. 3F**). As was the case for oral keratinocytes (e.g. OKF6 cells), the silencing of RIPK4 in epidermal keratinocytes also inhibited the PMA-inducible expression of CXCL11 (**Fig. 3G**) and IL8 (**Fig. 3H**). Together these results indicate that RIPK4 functions downstream of PKC to regulate the expression of proinflammatory cytokines in both oral and epidermal keratinocytes.

3.4 IRF6 regulates the induction of proinflammatory cytokine expression by the PKC pathway in keratinocytes

We recently established that RIPK4 promotes keratinocyte differentiation by directly stimulating the transactivator function of IRF6 [17]. IRF6 also functions in the TLR2 pathway to stimulate proinflammatory cytokine expression in oral keratinocytes [25]. Therefore, a role for IRF6 in mediating the expression of proinflammatory cytokines in response to PKC activation was investigated. The transfection of OKF6 cells with an IRF6 siRNA, which reduced IRF6 expression by >75% (**Fig. 4A**), strongly inhibited (>80%) the stimulation of CCL5 gene expression by PMA (**Fig. 4B**). Likewise, the silencing of IRF6 also inhibited the PMA-inducible expression of CXCL11 (**Fig. 4C**) and IL8 (**Fig. 4D**). In contrast, the stimulation of TNF gene expression was not significantly affected (data not shown). Comparable findings were obtained when IRF6 expression in normal human epidermal

keratinocytes was silenced. Specifically, the silencing of IRF6 significantly inhibited the PMA-inducible expression of CCL5 (**Fig. 4E**), CXCL11 (**Fig. 4F**), and IL8 (**Fig. 4G**). These findings are consistent with IRF6 functioning together with RIPK4 to regulate the expression of specific proinflammatory cytokines (e.g. CCL5 and CXCL11) in response to the activation of the PKC pathway in keratinocytes.

3.5 RIPK4 stimulates the IRF6-mediated transactivation of the CCL5 and CXCL11 promoters

The regulation of CCL5, CXCL11 and IL8 gene expression by RIPK4 and IRF6 was investigated further by performing gene promoter reporter assays in HEK293T cells. As shown in **Fig. 5A**, the co-expression of Ripk4 and IRF6 resulted in the strong (>50-fold) transactivation of the CCL5 promoter. Ripk4 activated only weakly (<10-fold) the gene reporter in the absence of co-expressed IRF6, and IRF6 was unable to activate the reporter in the absence of co-transfected Ripk4 (**Fig. 5A**). The co-expression of Ripk4 resulted in the strong (>30-fold) transactivation of the CXCL11 promoter by IRF6 (**Fig. 5B**). Again, Ripk4 activated only weakly the CXCL11 gene reporter in the absence of co-transfected IRF6 (**Fig. 5B**). In contrast to the CCL5 and CXCL11 gene reporters, Ripk4 strongly activated (>150-fold) the IL8 gene reporter in the absence of co-expressed IRF6 (**Fig. 5C**), and co-transfection of IRF6 resulted in a small, but significant, additional increase in reporter activity (**Fig. 5C**). These findings suggest that RIPK4 regulates CCL5 and CXCL11 gene expression by stimulating the transactivation of their promoters by IRF6.

4. Discussion

In addition to being important for maintaining the barrier functions of the oral mucosa and epidermis, keratinocytes also play active roles in host defense by producing cytokines that elicit inflammation in response to infection or injury [4, 5]. RIPK4 has previously been shown

to be a key regulator of keratinocyte differentiation [12, 17]. In the current study, we identified an additional role for RIPK4 in keratinocytes, namely in regulating the expression of proinflammatory cytokines. Therefore, RIPK4 likely plays a multifaceted role in the maintenance of epithelial homeostasis, and thus host defense, through its regulation of both keratinocyte inflammation and differentiation.

A role for RIPK4 in regulating the inflammatory properties of keratinocytes was suggested by the finding that the overexpression of RIPK4 in oral keratinocytes (e.g. OKF6 cells) was sufficient to induce the strong expression of CCL5 and CXCL11. Notably, the expression of other proinflammatory cytokines (e.g. IL8 and TNF) was largely unaffected, indicating that the induction of CCL5 and CXCL11 gene expression was directly and specifically correlated with increased RIPK4 levels. Therefore, RIPK4 activation in response to infection or injury is likely to be important in mediating the expression of CCL5 and CXCL11 by keratinocytes.

We recently demonstrated that RIPK4 mediates keratinocyte differentiation downstream of PKC activation by forming a signaling axis with IRF6 to induce the expression of differentiation-associated genes (e.g. GRHL3) [17]. Our findings here suggest that RIPK4 likewise cooperates with IRF6 to mediate the stimulation of proinflammatory cytokine expression by the PKC pathway in keratinocytes. Specifically, RIPK4 and IRF6 were shown to be necessary for the stimulation of CCL5 and CXCL11 gene expression by PMA. In line with their expression being directly regulated by the RIPK4-IRF6 pathway, the co-expression of RIPK4 and IRF6 induced the synergistic transactivation of the CCL5 and CXCL11 gene promoters. RIPK4 also stimulates the transactivator functions NF- κ B and AP-1 downstream of PKC activation [16, 17, 21]. We have shown previously that IRF6 functions in concert with NF- κ B to induce CCL5 gene expression downstream of TLR2 activation in oral keratinocytes (e.g. OKF6 cells) [25]. Similarly, IRF1 functionally cooperates with NF- κ B to regulate respiratory syncytial virus-inducible CCL5 expression in lung epithelial cells [30], and

interferon-inducible CXCL11 expression in B-lymphoblast cells [31]. Therefore, RIPK4 likely induces the expression of CCL5 and CXCL11 in keratinocytes by activating the transactivator functions of both NF- κ B and IRF6.

RIPK4 and IRF6 were also shown to be important for the PMA-inducible expression of IL8 in keratinocytes. In addition to NF- κ B and AP-1 [29, 32, 33], IRFs have also been demonstrated to play a role in regulating IL8 gene expression in epithelial cells [34-36]. Similar to CCL5 and CXCL11, maximal stimulation of IL8 gene expression by the PKC pathway in keratinocytes is likely to require functional cooperation between NF- κ B, AP-1 and IRF6 downstream of RIPK4 activation. Interestingly, RIPK4 was shown by gene reporter assay in HEK293T cells to activate the IL-8 promoter in the absence of IRF6. However, the co-transfection of IRF6 potentiated the activation of the IL8 gene reporter by RIPK4, and therefore HEK293T cells may express IRF family members that can functionally compensate for IRF6 to mediate the transactivation of the IL8 promoter.

The IRF6-dependent stimulation of IL8 expression by PKC in OKF6 cells contrasted with its IRF6-independent regulation by TLR2 [25]. The differences in the dependence on IRF6 for the activation of IL8 transcription may provide a mechanism for imparting signaling specificity to the stimulation of IL8 production by the PKC and TLR2 pathways in keratinocytes. This may in turn be important in dictating the nature of the inflammatory responses elicited by different stimuli. However, further studies are required to fully understand the mechanisms of IRF6 action in regulating IL8 expression.

The overexpression of RIPK4 in OKF6 cells was not sufficient to induce TNF gene expression, despite the fact that TNF expression is largely regulated by NF- κ B and AP-1 [37, 38]. However, RIPK4 was necessary for the PMA-inducible expression of TNF. This indicates that PKC likely stimulates TNF expression via both RIPK4-dependent and RIPK4-independent pathways. Notably, IRF6 was not required for the stimulation of TNF expression by PKC. IRF5 has been shown to functionally cooperate with NF- κ B in regulating TNF gene

expression by the TLR4 pathway in myeloid cells [39]. Therefore, IRFs may contribute to the differential regulation of TNF expression in a cell-type or stimulus dependent manner.

CCL5 stimulates the recruitment of various immune cell populations, including T cells, monocytes, eosinophils, and mast cells [40, 41]. CXCL11 acts via chemokine (C-X-C motif) receptor 3 (CXCR3) to stimulate the recruitment of inflammatory T cells (e.g. Th1 and Th17 cells) [42], whereas IL8 is a key regulator of the trafficking and homing of neutrophils [6]. Mouse models of infection have demonstrated that CCL5, CXCL11 and IL8 are important mediators of host defense [43-49]. Accordingly, our findings potentially position RIPK4 as a key regulator of the inflammatory responses of the oral mucosa and epidermis to microbial pathogens through its control of IRF6-mediated inflammatory cytokine expression in keratinocytes. Such a conclusion is consistent with the finding that the transgenic expression of *Ripk4* in the epidermis of mice caused spontaneous inflammation [24], and exacerbated the epidermal inflammation induced by the topical application of the well-established skin irritant PMA.

We recently demonstrated a role for IRF6 in mediating the inflammatory cytokine responses of oral keratinocytes to *Porphyromonas gingivalis* [50], a keystone pathogen in periodontitis. In this context, IRF6 transactivator function was regulated at least in part by IL-1R-associated kinase 1. However, the findings presented in this study raise the possibility that RIPK4 may also play a role in promoting oral inflammation to *P. gingivalis*, and potentially other pathogens, through its activation of IRF6.

In addition to producing proinflammatory cytokines, activated keratinocytes are also migratory and hyperproliferative, and facilitate re-epithelialization following damage to surface epithelia (e.g. oral mucosa and epidermis). Once re-epithelialization is complete, the activated keratinocytes revert to differentiation to restore the functional integrity of the epithelium [51]. In addition to T cells, CXCL11 can also stimulate keratinocyte migration [52, 53], and CXCL11 has been shown to be produced by keratinocytes in an excisional wound

healing model [54]. Significantly, wound closure and re-epithelialization was delayed in Cxcl11-deficient [52] and Cxcr3-deficient mice [54]. However, given that T cells can produce growth factors which stimulate keratinocyte and fibroblast proliferation [55, 56], CXCL11 may promote wound healing by acting in both an autocrine and paracrine manner. Therefore, in addition to its regulation of keratinocyte differentiation, RIPK4 may also promote wound healing by stimulating wound closure and re-epithelialization through its regulation of CXCL11 expression.

In conclusion, our findings extend the RIPK4-IRF6 signaling axis to the regulation of proinflammatory cytokine expression, particularly in oral keratinocytes. As the oral epithelium is pivotal as both a physical barrier and an immune tissue, this potentially places RIPK4 in the signaling framework as an important regulator of the inflammatory response of the oral mucosa following infection or injury. Moreover, by governing both keratinocyte inflammation and differentiation, RIPK4 may function as a key regulatory nodal point in the maintenance of epithelial homeostasis. For the same reason, because the dysregulation of this signaling framework may lead to chronic inflammation, future studies aimed at exploring the role of the RIPK4-IRF6 axis in the context of chronic inflammatory diseases offer the potential for therapeutic exploitation.

373 **Acknowledgements**

374 The authors thank Drs Michael Beard (University of Adelaide), Allan Brasier (University of
375 Texas Medical Branch), Shiv Pillai (Harvard Medical School), and Paula Pitha (Johns
376 Hopkins University) for generously providing plasmids.

377

378 **Funding**

379 Supported by the Australian Government, Department of Industry, Innovation and Science,
380 and National Health and Medical Research Council Project Grant 628769.

381

382 **Conflict of Interest**

383 The authors declare no conflicts of interest.

384

References

- [1] Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. *Annu Rev Pathol.* 2010;5:119-44.
- [2] Donati G, Watt FM. Stem cell heterogeneity and plasticity in epithelia. *Cell Stem Cell.* 2015;16:465-76.
- [3] Polimeni G, Xiropaidis AV, Wikesjo UM. Biology and principles of periodontal wound healing/regeneration. *Periodontol 2000.* 2006;41:30-47.
- [4] Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol.* 2014;14:289-301.
- [5] Miller LS. Toll-like receptors in skin. *Adv Dermatol.* 2008;24:71-87.
- [6] Kobayashi Y. Neutrophil infiltration and chemokines. *Crit Rev Immunol.* 2006;26:307-16.
- [7] Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. *Nat Rev Microbiol.* 2010;8:481-90.
- [8] Li J, Ireland GW, Farthing PM, Thornhill MH. Epidermal and oral keratinocytes are induced to produce RANTES and IL-8 by cytokine stimulation. *J Invest Dermatol.* 1996;106:661-6.
- [9] Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. *Trends Immunol.* 2001;22:83-7.
- [10] Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. *Trends Immunol.* 2013;34:174-81.
- [11] Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. *Immunol Rev.* 2011;242:233-46.
- [12] Holland P, Willis C, Kanaly S, Glaccum M, Warren A, Charrier K, et al. RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation. *Curr Biol.* 2002;12:1424-8.

410 [13] Kalay E, Sezgin O, Chellappa V, Mutlu M, Morsy H, Kayserili H, et al. Mutations in
 411 RIPK4 cause the autosomal-recessive form of popliteal pterygium syndrome. *Am J Hum*
 412 *Genet.* 2012;90:76-85.

413 [14] Mitchell K, O'Sullivan J, Missero C, Blair E, Richardson R, Anderson B, et al. Exome
 414 sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus. *Am J Hum Genet.*
 415 2012;90:69-75.

416 [15] Chen L, Haider K, Ponda M, Cariappa A, Rowitch D, Pillai S. Protein kinase C-
 417 associated kinase (PKK), a novel membrane-associated, ankyrin repeat-containing protein
 418 kinase. *J Biol Chem.* 2001;276:21737-44.

419 [16] Muto A, Ruland J, McAllister-Lucas LM, Lucas PC, Yamaoka S, Chen FF, et al. Protein
 420 kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation
 421 induced by phorbol ester. *J Biol Chem.* 2002;277:31871-6.

422 [17] Kwa MQ, Huynh J, Aw J, Zhang L, Nguyen T, Reynolds EC, et al. Receptor-interacting
 423 Protein Kinase 4 and Interferon Regulatory Factor 6 Function as a Signaling Axis to Regulate
 424 Keratinocyte Differentiation. *J Biol Chem.* 2014;289:31077-87.

425 [18] Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, et al. Abnormal skin,
 426 limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6).
 427 *Nat Genet.* 2006;38:1335-40.

428 [19] Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP, et al.
 429 Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. *Nat Genet.*
 430 2006;38:1329-34.

431 [20] de la Garza G, Schleiffarth JR, Dunnwald M, Mankad A, Weirather JL, Bonde G, et al.
 432 Interferon regulatory factor 6 promotes differentiation of the periderm by activating
 433 expression of Grainyhead-like 3. *J Invest Dermatol.* 2013;133:68-77.

434 [21] Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. RIP4 (DIK/PKK), a novel
435 member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis.
436 EMBO Rep. 2002;3:1201-8.

437 [22] Kwa MQ, Huynh J, Reynolds EC, Hamilton JA, Scholz GM. Disease-associated
438 mutations in IRF6 and RIPK4 dysregulate their signalling functions. Cell Signal.
439 2015;27:1509-16.

440 [23] Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications
441 for inflammatory diseases. Nat Rev Immunol. 2009;9:778-88.

442 [24] Rountree RB, Willis CR, Dinh H, Blumberg H, Bailey K, Dean C, Jr., et al. RIP4
443 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol.
444 2010;130:102-12.

445 [25] Kwa MQ, Nguyen T, Huynh J, Ramnath D, De Nardo D, Lam PY, et al. Interferon
446 regulatory factor 6 differentially regulates Toll-like receptor 2-dependent chemokine gene
447 expression in epithelial cells. J Biol Chem. 2014;289:19758-68.

448 [26] Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR.
449 Nucleic Acids Res. 2001;29:e45.

450 [27] Lin R, Genin P, Mamane Y, Hiscott J. Selective DNA binding and association with the
451 CREB binding protein coactivator contribute to differential activation of alpha/beta interferon
452 genes by interferon regulatory factors 3 and 7. Mol Cell Biol. 2000;20:6342-53.

453 [28] Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, et al.
454 Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection
455 and their modulation by HCV in vitro. J Virol. 2009;83:836-46.

456 [29] Garofalo R, Sabry M, Jamaluddin M, Yu RK, Casola A, Ogra PL, et al. Transcriptional
457 activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar
458 epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism
459 producing airway mucosal inflammation. J Virol. 1996;70:8773-81.

460 [30] Casola A, Garofalo RP, Haeberle H, Elliott TF, Lin R, Jamaluddin M, et al. Multiple cis
461 regulatory elements control RANTES promoter activity in alveolar epithelial cells infected
462 with respiratory syncytial virus. *J Virol.* 2001;75:6428-39.

463 [31] Yang CH, Wei L, Pfeffer SR, Du Z, Murti A, Valentine WJ, et al. Identification of
464 CXCL11 as a STAT3-dependent gene induced by IFN. *J Immunol.* 2007;178:986-92.

465 [32] Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8
466 promoter. *Mol Cell Biol.* 1993;13:6137-46.

467 [33] Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K. Tumor
468 necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in
469 a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding
470 sites of the interleukin 8 gene. *J Biol Chem.* 1992;267:22506-11.

471 [34] Casola A, Garofalo RP, Jamaluddin M, Vlahopoulos S, Brasier AR. Requirement of a
472 novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression.
473 *J Immunol.* 2000;164:5944-51.

474 [35] Wagoner J, Austin M, Green J, Imaizumi T, Casola A, Brasier A, et al. Regulation of
475 CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during
476 hepatitis C virus infection. *J Virol.* 2007;81:309-18.

477 [36] Yamaoka Y, Kudo T, Lu H, Casola A, Brasier AR, Graham DY. Role of interferon-
478 stimulated responsive element-like element in interleukin-8 promoter in *Helicobacter pylori*
479 infection. *Gastroenterology.* 2004;126:1030-43.

480 [37] Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha
481 transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and
482 inducible forms of NF-kappa B. *Mol Cell Biol.* 1990;10:1498-506.

483 [38] Rhoades KL, Golub SH, Economou JS. The regulation of the human tumor necrosis
484 factor alpha promoter region in macrophage, T cell, and B cell lines. *J Biol Chem.*
485 1992;267:22102-7.

486 [39] Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA. IRF5 is
 487 required for late-phase TNF secretion by human dendritic cells. *Blood*. 2010;115:4421-30.

488 [40] Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T
 489 lymphocytes of the memory phenotype by cytokine RANTES. *Nature*. 1990;347:669-71.

490 [41] Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine
 491 RANTES released by thrombin-stimulated platelets is a potent attractant for human
 492 eosinophils. *J Exp Med*. 1992;176:587-92.

493 [42] Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-
 494 inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with
 495 potent activity on activated T cells through selective high affinity binding to CXCR3. *J Exp*
 496 *Med*. 1998;187:2009-21.

497 [43] Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S. CXCL1 regulates pulmonary host
 498 defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. *J Immunol*.
 499 2010;185:6214-25.

500 [44] Jin L, Batra S, Douda DN, Palaniyar N, Jeyaseelan S. CXCL1 contributes to host defense
 501 in polymicrobial sepsis via modulating T cell and neutrophil functions. *J Immunol*.
 502 2014;193:3549-58.

503 [45] Spehlmann ME, Dann SM, Hruz P, Hanson E, McCole DF, Eckmann L. CXCR2-
 504 dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an
 505 attaching/effacing lesion-forming bacterial pathogen. *J Immunol*. 2009;183:3332-43.

506 [46] Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, et al. CCL5-CCR5
 507 interaction provides antiapoptotic signals for macrophage survival during viral infection. *Nat*
 508 *Med*. 2005;11:1180-7.

509 [47] Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, et al. CCL5
 510 modulates pneumococcal immunity and carriage. *J Immunol*. 2006;176:2346-56.

511 [48] Vesosky B, Rottinghaus EK, Stromberg P, Turner J, Beamer G. CCL5 participates in
512 early protection against *Mycobacterium tuberculosis*. *J Leukoc Biol*. 2010;87:1153-65.

513 [49] Foley JF, Yu CR, Solow R, Yacobucci M, Peden KW, Farber JM. Roles for CXC
514 chemokine ligands 10 and 11 in recruiting CD4⁺ T cells to HIV-1-infected monocyte-derived
515 macrophages, dendritic cells, and lymph nodes. *J Immunol*. 2005;174:4892-900.

516 [50] Huynh J, Scholz GM, Aw J, Kwa MQ, Achuthan A, Hamilton JA, et al. IRF6 Regulates
517 the Expression of IL-36gamma by Human Oral Epithelial Cells in Response to
518 *Porphyromonas gingivalis*. *J Immunol*. 2016;196:2230-8.

519 [51] Martin P. Wound healing--aiming for perfect skin regeneration. *Science*. 1997;276:75-
520 81.

521 [52] Yates CC, Whaley D, A YC, Kulesekaran P, Hebda PA, Wells A. ELR-negative CXC
522 chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound
523 repair. *Am J Pathol*. 2008;173:643-52.

524 [53] Satish L, Blair HC, Glading A, Wells A. Interferon-inducible protein 9 (CXCL11)-
525 induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-
526 calpain. *Mol Cell Biol*. 2005;25:1922-41.

527 [54] Yates CC, Whaley D, Kulasekeran P, Hancock WW, Lu B, Bodnar R, et al. Delayed and
528 deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine
529 receptor. *Am J Pathol*. 2007;171:484-95.

530 [55] Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes
531 synthesize and export heparin-binding epidermal growth factor-like growth factor and basic
532 fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production
533 and release by CD4⁺ and CD8⁺ T cells. *Proc Natl Acad Sci U S A*. 1994;91:2890-94.

534 [56] Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for skin
535 gammadelta T cells in wound repair. *Science*. 2002;296:747-9.

536

Figure Legends

Fig. 1. Overexpression of RIPK4 in human keratinocytes induces proinflammatory cytokine expression and secretion. OKF6 cells were transfected with a FLAG-Ripk4 expression plasmid or empty plasmid. Twenty-four h post-transfection, (A) Ripk4, (C) IL8, (E) TNF, (F) CCL5, and (H) CXCL11 mRNA levels were measured by qPCR. Ripk4 mRNA levels are shown relative to HPRT, and IL8, TNF, CCL5 and CXCL11 mRNA levels as the –fold increase over cells transfected with empty plasmid. (B) Cell lysates were subjected to Western blotting with anti-FLAG and anti-HSP90 (loading control) antibodies. (D) IL8 and (G) CCL5 protein levels in the cell culture medium were measured by ELISA. All data are combined from three independent experiments and presented as the mean $\pm$ SEM (** $p < 0.01$, * $p < 0.05$, ND = Not detected).

Fig. 2. Stimulation of proinflammatory cytokine expression in human keratinocytes by PMA. OKF6 cells were treated with PMA for the times indicated. (A) CCL5, (B) CXCL11, (C) IL8, (D) TNF, and (E) RIPK4 mRNA levels were measured by qPCR and are shown as the –fold increase over control cells. All data are combined from at least three independent experiments and presented as the mean $\pm$ SEM (** $p < 0.01$, * $p < 0.05$).

Fig. 3. RIPK4-dependent stimulation of proinflammatory cytokine expression in human keratinocytes by PMA. (A-E) OKF6 cells and (F-H) normal human epidermal keratinocytes were transfected with a RIPK4 (+) or control (-) siRNA. Forty-eight h post-transfection, (A) RIPK4 mRNA levels were measured by qPCR. RIPK4 mRNA levels in cells transfected with the control siRNA were given an arbitrary value of 100%. (B-H) The cells were treated with PMA for 2 h (TNF) or 6 h (CCL5, CXCL11 and IL8). (B and F) CCL5, (C and G) CXCL11, (D and H) IL8, and (E) TNF mRNA

levels were measured by qPCR and are shown as the –fold increase over control cells.

All data are combined from three independent experiments and presented as the mean $\pm$

SEM (** $p < 0.01$, * $p < 0.05$).

Fig. 4. IRF6-dependent stimulation of proinflammatory cytokine expression in human keratinocytes by PMA. (A-D) OKF6 cells and (E-G) normal human epidermal keratinocytes were transfected with an IRF6 (+) or control (-) siRNA. Forty-eight h post-transfection, (A) IRF6 mRNA levels were measured by qPCR. IRF6 mRNA levels in cells transfected with the control siRNA were given an arbitrary value of 100%. (B-G) The cells were treated with PMA for 2 h (TNF) or 6 h (CCL5, CXCL11 and IL8). (B and E) CCL5, (C and F) CXCL11, and (D and G) IL8 mRNA levels were measured by qPCR and are shown as the –fold increase over control cells. All data are combined from three independent experiments and presented as the mean $\pm$ SEM (** $p < 0.01$, * $p < 0.05$).

Fig. 5. RIPK4 stimulates the transactivation of the CCL5 and CXCL11 gene promoters by IRF6. HEK293T cells were transfected with an (A) CCL5, (B) CXCL11, and (C) IL8 gene promoter reporter plasmid together with plasmids expressing Ripk4 and IRF6. Gene reporter activity was measured 24 h post-transfection and shown as the –fold increase over cells transfected with empty plasmid. All data are combined from three independent experiments and presented as the mean $\pm$ SEM (** $p < 0.01$, * $p < 0.05$).

Figure 1

Figure 2

Figure 3
[Click here to download high resolution image](#)

Figure 3

Figure 4
[Click here to download high resolution image](#)

Figure 4

Figure 5

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kwa, MQ;Scholz, GM;Reynolds, EC

Title:

RIPK4 activates an IRF6-mediated proinflammatory cytokine response in keratinocytes

Date:

2016-07-01

Citation:

Kwa, M. Q., Scholz, G. M. & Reynolds, E. C. (2016). RIPK4 activates an IRF6-mediated proinflammatory cytokine response in keratinocytes. CYTOKINE, 83, pp.19-26. <https://doi.org/10.1016/j.cyto.2016.03.005>.

Persistent Link:

<http://hdl.handle.net/11343/108650>